Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2025)

C4 Therapeutics (CCCC) has 6 years of Depreciation and Depletion data on record, last reported at $377000.0 in Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 3.57% year-over-year to $377000.0; the TTM value through Dec 2025 reached $1.5 million, up 4.62%, while the annual FY2025 figure was $1.5 million, 4.62% up from the prior year.
  • Depreciation and Depletion reached $377000.0 in Q4 2025 per CCCC's latest filing, down from $384000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $545000.0 in Q1 2023 and bottomed at $128000.0 in Q4 2023.
  • Average Depreciation and Depletion over 5 years is $387750.0, with a median of $380500.0 recorded in 2025.
  • Peak YoY movement for Depreciation and Depletion: plummeted 75.43% in 2023, then surged 184.38% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $323000.0 in 2021, then surged by 61.3% to $521000.0 in 2022, then tumbled by 75.43% to $128000.0 in 2023, then soared by 184.38% to $364000.0 in 2024, then increased by 3.57% to $377000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $377000.0 in Q4 2025, $384000.0 in Q3 2025, and $416000.0 in Q2 2025.